ReviewExpert review of vaccines2010
Phase III HIV vaccine trial in Thailand: a step toward a protective vaccine for HIV.
Review in Expert review of vaccines, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 60 citations in OpenAlex.
- Trial
- First Phase I human clinical trial of a killed whole-HIV-1 vaccine: demonstration of its safety and enhancement of anti-HIV antibody responses.Retrovirology · 2016Trial
- The Thai phase III trial (RV144) vaccine regimen induces T cell responses that preferentially target epitopes within the V2 region of HIV-1 envelope.Journal of immunology (Baltimore, Md. : 1950) · 2012Trial
- Understanding the performance of HIV-1 viral vector vaccines: adenovirus and poxvirus case studies.Frontiers in immunology · 2025Review
- Enhanced HIV immune responses elicited by an apoptotic single-cycle SHIV lentivector DNA vaccine.Frontiers in cellular and infection microbiology · 2025Article
- Exploring HIV Vaccine Progress in the Pre-Clinical and Clinical Setting: From History to Future Prospects.Viruses · 2024Review
- SARS-CoV-2 Vaccine Development: An Overview and Perspectives.ACS pharmacology & translational science · 2020Review
- Article
- Using Mobile Technology (pMOTAR) to Assess Reactogenicity: Protocol for a Pilot Randomized Controlled Trial.JMIR research protocols · 2018Article
- Article
- Immunogenicity and efficacy of DNA/MVA HIV vaccines in rhesus macaque models.Expert review of vaccines · 2017Review
- Killed whole-HIV vaccine; employing a well established strategy for antiviral vaccines.AIDS research and therapy · 2017Review
- Membrane-anchored CCL20 augments HIV Env-specific mucosal immune responses.Virology journal · 2017Article
- Recent Insights into the HIV/AIDS Pandemic.Microbial cell (Graz, Austria) · 2016Review
- Concurrency and Other Sexual Risk Behaviors Among Black Young Adults in a Southeastern City.AIDS education and prevention : official publication of the International Society for AIDS Education · 2016Article
- Perceptions of and intentions to adopt HIV pre-exposure prophylaxis among black men who have sex with men in Los Angeles.International journal of STD & AIDS · 2015Article
- Can We Repurpose FDA-Approved Alefacept to Diminish the HIV Reservoir?Immunotherapy (Los Angeles, Calif.) · 2015Article
- Teachers' patterns of implementation of an evidence-based intervention and their impact on student outcomes: results from a nationwide dissemination over 24-months follow-up.AIDS and behavior · 2015Article
- Designing synthetic vaccines for HIV.Expert review of vaccines · 2015Review
- RNA interference approaches for treatment of HIV-1 infection.Genome medicine · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
The large human efficacy trail in Thailand, RV144, was concluded in the summer of 2009. This is the first Phase III trial to show limited, but significant, efficacy in preventing HIV acquisition. This trial represents the first sign that a preventive vaccine for HIV may be feasible. The vaccine regimen tested in Thailand consisted of priming with a Canarypox vector carrying three synthetic HIV genes. The priming was followed by booster inoculations with two recombinant envelope proteins from HIV, clade B and E. The need to understand the role in protection from HIV acquisition of the new responses, induced by this vaccine combination, has brought together many researchers with the common goal of improving the development of a safe and effective vaccine for HIV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.